Thursday, 2 December 2021

Australia's most trusted
source of pharma news

Thursday, 02 December 2021

TGA off-label drug use warning

Posted 27 October 2021 AM

The TGA has issued a medicines safety update, warning healthcare professionals of the risk of atrioventricular block - including complete heart block resulting in cardiac arrest - when using octreotide off-label in Australia.

Octreotide, marketed in Australia by Novartis under the brand names Sandostatin and Sandostatin LAR, as well as various generic brands by Generic Health, Pfizer, Sun Pharma and Teva Pharma, is an octapeptide that mimics natural somatostain pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon and insulin than the natural hormone.

To see the whole article, please login

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.